drugset / Trial / NCT02185066

Phase 1 Study to Compare the Safety, Pharmacokinetic Profiles of CJ-30056 and Lipitor/Glucophage XR

NCT02185066

Phase 1 Completed 42 enrolled HK inno.N Corporation
RandomizedCrossoverOpen-labelTreatment

Summary

This study is designed to evaluate safety and pharmacokinetic properties of the two treatments, the administration of CJ-30056 and the co-administration of atorvastatin and metformin XR, in healthy volunteers.

Timeline

Start
2014-07
Primary completion
2014-09
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 20 mg Oral
Subject CJ-30056 Unknown Oral
Subject Metformin Small molecule 500 mg Oral

Indications

No indication recorded.